OPKO HEALTH, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.26 USD | +3.28% |
|
+2.44% | -16.56% |
| Sales 2024 * | 745M 59.66B | Sales 2025 * | 796M 63.69B | Capitalization | 878M 70.3B |
|---|---|---|---|---|---|
| Net income 2024 * | -259M -20.73B | Net income 2025 * | -185M -14.81B | EV / Sales 2024 * | 1.18 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.1 x |
| P/E ratio 2024 * |
-3.45
x | P/E ratio 2025 * |
-4.91
x | Employees | 3,930 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 47.01% |
More Fundamentals
* Assessed data
More news
Latest transcript on OPKO Health, Inc.
More recommendations
More press releases
More news
| 1 day | +3.28% | ||
| 1 week | +2.44% | ||
| Current month | +5.00% | ||
| 1 month | +17.76% | ||
| 3 months | +27.97% | ||
| 6 months | +2.44% | ||
| Current year | -16.56% |
1 week
1.19
1.28
1 month
1.191.43
Current year
0.851.57
1 year
0.852.24
3 years
0.855.25
5 years
0.856.47
10 years
0.8519.20
| Managers | Title | Age | Since |
|---|---|---|---|
Phillip Frost
CEO | Chief Executive Officer | 87 | 26/03/07 |
Adam Logal
DFI | Director of Finance/CFO | 46 | 28/02/07 |
Elias Zerhouni
PSD | President | 72 | 08/05/22 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Phillip Frost
CEO | Chief Executive Officer | 87 | 26/03/07 |
Roger Medel
BRD | Director/Board Member | 77 | 17/12/20 |
| Director/Board Member | 68 | 31/12/07 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.07% | 0 M€ | 0.00% | - | |
| 0.07% | 509 M€ | -.--% | ||
| 0.06% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 1.26 | +3.28% | 1,947,676 |
| 25/04/24 | 1.22 | -0.81% | 4,751,377 |
| 24/04/24 | 1.23 | -1.60% | 6,063,826 |
| 23/04/24 | 1.25 | +1.63% | 2,387,338 |
| 22/04/24 | 1.23 | 0.00% | 3,627,063 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company's diagnostics segment consists of the clinical laboratory operations of BioReference Health, LLC (BioReference), its point-of-care operations. Its pharmaceutical segment consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. Through BioReference, it operates specialized laboratory divisions, such as GenPath (Urology), GenPath (Oncology), and GenPath (Women's Health). It has two commercial stage pharmaceutical products and several pharmaceutical compounds and technologies in various stages of research and development for a range of indications and conditions, including Rayaldee, Rayaldee, Oxyntomodulin, Biologics, NGENLA Somatrogon, and Factor VIIa-CTP. It develops and manufactures specialty active pharmaceutical ingredients (APIs) through FineTech Pharmaceutical, Ltd.
Calendar
05/05/2024
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.26
USD
Average target price
4.25
USD
Spread / Average Target
+237.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -16.56% | 878M | |
| -17.89% | 8.25B | |
| +39.20% | 3.58B | |
| -39.11% | 2.46B | |
| -8.06% | 2.46B | |
| -7.35% | 2.38B | |
| -12.61% | 1.81B | |
| -19.01% | 1.55B | |
| -40.66% | 1.21B | |
| +7.56% | 1.11B |
- Stock Market
- Equities
- OPK Stock
